美国 · SEC FORM 4
COGNITION THERAPEUTICS INC
CGTX · Nasdaq · CIK 0001455365 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
6 同一窗口内观察到的 Form 4 交易行
0 sales · 6 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-04-16 · Doyle John Brendan · $11.3K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Khattar Jack A.Director
○
Monia Brett PDirector
○
Wallace PeggyDirector
○
RICHSTONE ELLEN BDirector
○
BIOS Advisors GP, LLC; BIOS Capital Management, LP; BIOS Fund I QP, LP; BIOS Fund I, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Memory SPV I, LP; Bios Equity Partners II, LP; Bios Equity Partners, LP; Fletcher Aaron G.L.Director,TenPercentOwner
○
Doyle John BrendanChief Financial Officer
○
● 买入▼ 卖出○ 其他
—
信号历史
48.4 / 100
最新留档分数
↓ -0.1 pts相对上一个留档快照
- 55.5
- 48.5
- 48.4
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
3买入
0卖出
23其他 Form 4 交易行
18SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他6 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -10.5%
- 3M
- -14.0%
- 6M
- -3.1%
- 12M
- -50.2%
波动率与流动性
- 波动率
- 123.2%
- Beta
- —
- 平均每日成交额
- USD 424,231
估值
- 市值
- USD 83.4M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -68.5%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-04 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 7,579,141
- 上期报告
- 7,740,997
- 日均成交量
- 455,659
- 回补天数
- 16.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-16 | Ricciardi Lisa | 买入 (P) | Common Stock | 9,175 | USD 1.10 | USD 10,092 | SEC 申报 ↗ |
| 2026-04-16 | Doyle John Brendan | 买入 (P) | Common Stock | 10,000 | USD 1.13 | USD 11,300 | SEC 申报 ↗ |
| 2026-04-16 | Caggiano Anthony | 买入 (P) | Common Stock | 10,000 | USD 1.11 | USD 11,100 | SEC 申报 ↗ |
| 2025-01-31 | Ricciardi Lisa | 买入 (P) | Common Stock | 38,851 | USD 0.77 | USD 29,915 | SEC 申报 ↗ |
| 2024-03-14 | Ricciardi Lisa | 买入 (P) | Common Stock | 5,700 | USD 1.75 | USD 9,975 | SEC 申报 ↗ |
| 2022-11-29 | RICHSTONE ELLEN B | 买入 (P) | Common Stock | 10,000 | USD 2.66 | USD 26,600 | SEC 申报 ↗ |
| 2022-11-28 | BIOS Equity Partners III, LP; BIOS Fund II NT, LP; BIOS Fund III NT, LP; BIOS Fund III QP, LP; BIOS Fund III, LP; BIOS Memory SPV II, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W. | 买入 (P) | Common Stock | 16,064 | USD 2.65 | USD 42,570 | SEC 申报 ↗ |
| 2022-11-28 | BIOS Advisors GP, LLC; BIOS Capital Management, LP; BIOS Fund I QP, LP; BIOS Fund I, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Memory SPV I, LP; Bios Equity Partners II, LP; Bios Equity Partners, LP; Fletcher Aaron G.L. | 买入 (P) | Common Stock | 16,064 | USD 2.65 | USD 42,570 | SEC 申报 ↗ |
| 2022-11-16 | BIOS Equity Partners III, LP; BIOS Fund II NT, LP; BIOS Fund III NT, LP; BIOS Fund III QP, LP; BIOS Fund III, LP; BIOS Memory SPV II, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W. | 买入 (P) | Common Stock | 71,000 | USD 1.40 | USD 99,400 | SEC 申报 ↗ |
| 2022-11-16 | BIOS Advisors GP, LLC; BIOS Capital Management, LP; BIOS Fund I QP, LP; BIOS Fund I, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Memory SPV I, LP; Bios Equity Partners II, LP; Bios Equity Partners, LP; Fletcher Aaron G.L. | 买入 (P) | Common Stock | 71,000 | USD 1.40 | USD 99,400 | SEC 申报 ↗ |
| 2022-11-15 | Wallace Peggy | 买入 (P) | Common Stock | 12,500 | USD 1.20 | USD 15,000 | SEC 申报 ↗ |
| 2022-11-15 | Ricciardi Lisa | 买入 (P) | Common Stock | 12,000 | USD 1.30 | USD 15,600 | SEC 申报 ↗ |
| 2022-11-15 | BIOS Equity Partners III, LP; BIOS Fund II NT, LP; BIOS Fund III NT, LP; BIOS Fund III QP, LP; BIOS Fund III, LP; BIOS Memory SPV II, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W. | 买入 (P) | Common Stock | 1,500,000 | USD 1.20 | USD 1,800,000 | SEC 申报 ↗ |
| 2022-11-15 | BIOS Advisors GP, LLC; BIOS Capital Management, LP; BIOS Fund I QP, LP; BIOS Fund I, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Memory SPV I, LP; Bios Equity Partners II, LP; Bios Equity Partners, LP; Fletcher Aaron G.L. | 买入 (P) | Common Stock | 1,500,000 | USD 1.20 | USD 1,800,000 | SEC 申报 ↗ |
| 2021-10-13 | Wallace Peggy | 买入 (P) | Common Stock | 3,000 | USD 12.00 | USD 36,000 | SEC 申报 ↗ |
Form 4 申报证据
26 transaction lines in the latest 365-day window; 157 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Wallace Peggy | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | RICHSTONE ELLEN B | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Monia Brett P | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (26 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Wallace Peggy | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | RICHSTONE ELLEN B | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Monia Brett P | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Khattar Jack A. | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | BIOS Advisors GP, LLC; BIOS Capital Management, LP; BIOS Fund I QP, LP; BIOS Fund I, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Memory SPV I, LP; Bios Equity Partners II, LP; Bios Equity Partners, LP; Fletcher Aaron G.L. | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | Doyle John Brendan | 代扣税 (F) | Common Stock | 8,567 | USD 1.28 | USD 10,966 | SEC 申报 ↗ |
| 2026-04-16 | Ricciardi Lisa | 买入 (P) | Common Stock | 9,175 | USD 1.10 | USD 10,092 | SEC 申报 ↗ |
| 2026-04-16 | Doyle John Brendan | 买入 (P) | Common Stock | 10,000 | USD 1.13 | USD 11,300 | SEC 申报 ↗ |
| 2026-04-16 | Caggiano Anthony | 买入 (P) | Common Stock | 10,000 | USD 1.11 | USD 11,100 | SEC 申报 ↗ |
| 2026-02-15 | Ricciardi Lisa | 代扣税 (F) | Common Stock | 5,850 | USD 1.12 | USD 6,552 | SEC 申报 ↗ |
| 2026-02-15 | Doyle John Brendan | 代扣税 (F) | Common Stock | 1,560 | USD 1.12 | USD 1,747 | SEC 申报 ↗ |
| 2026-02-15 | Caggiano Anthony | 代扣税 (F) | Common Stock | 4,680 | USD 1.12 | USD 5,242 | SEC 申报 ↗ |
| 2026-02-04 | Ricciardi Lisa | 代扣税 (F) | Common Stock | 51,704 | USD 1.03 | USD 53,255 | SEC 申报 ↗ |
| 2026-02-04 | Doyle John Brendan | 代扣税 (F) | Common Stock | 26,921 | USD 1.03 | USD 27,729 | SEC 申报 ↗ |
| 2026-02-04 | Caggiano Anthony | 代扣税 (F) | Common Stock | 26,919 | USD 1.03 | USD 27,727 | SEC 申报 ↗ |
| 2026-02-03 | Ricciardi Lisa | 代扣税 (F) | Common Stock | 26,036 | USD 1.12 | USD 29,160 | SEC 申报 ↗ |
| 2026-02-03 | Ricciardi Lisa | 奖励／授予 (A) | Common Stock | 800,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-03 | Doyle John Brendan | 奖励／授予 (A) | Common Stock | 200,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-03 | Caggiano Anthony | 代扣税 (F) | Common Stock | 11,488 | USD 1.12 | USD 12,867 | SEC 申报 ↗ |
| 2026-02-03 | Caggiano Anthony | 奖励／授予 (A) | Common Stock | 400,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-18 | Ricciardi Lisa | 代扣税 (F) | Common Stock | 23,400 | USD 1.50 | USD 35,100 | SEC 申报 ↗ |
| 2025-12-18 | Ricciardi Lisa | 奖励／授予 (A) | Common Stock | 75,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-18 | Doyle John Brendan | 代扣税 (F) | Common Stock | 9,360 | USD 1.50 | USD 14,040 | SEC 申报 ↗ |
| 2025-12-18 | Doyle John Brendan | 奖励／授予 (A) | Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-18 | Caggiano Anthony | 代扣税 (F) | Common Stock | 20,280 | USD 1.50 | USD 30,420 | SEC 申报 ↗ |
| 2025-12-18 | Caggiano Anthony | 奖励／授予 (A) | Common Stock | 65,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CGTX |
| CIK | 0001455365 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 157 transaction lines from 2021-10-13 to 2026-06-17 35 P purchase lines · 5 S sale lines · 117 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.